FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3100291706> ?p ?o ?g. }

• W3100291706 endingPage "100608" @default.
• W3100291706 startingPage "100608" @default.
• W3100291706 abstract "Many improvements in head and neck cancer (HNC) outcomes are related to optimization of radiation therapy (RT) dose, fractionation, normal-tissue sparing, and technology. However, prior work has shown that the literature of randomized controlled trials is dominated by industry-sponsored trials that have lower rates of incorporating RT. We characterized HNC clinical trials, hypothesizing that RT-specific research questions may be relatively underrepresented among HNC randomized controlled trials.A web query of all open interventional trials on www.ClinicalTrials.gov was performed using search terms head and neck cancer and specific HNC subsites. Trial details were captured including the modality used, principal investigator (PI) specialty, funding, and whether the study tested a RT-modality specific hypothesis. Chi-square testing and logistic regression were used to compare groups.There were 841 open HNC trials, including definitive (47.6%) and recurrent/metastatic (41.9%) populations. Most trials (71.7%) were phase I or nonrandomized phase II studies, rather than phase III or randomized phase II (28.3%). Among single-arm studies, most (79.6%) incorporated systemic therapy (ST), and fewer (25.2%) incorporated RT. Even fewer phase III and randomized phase II trials tested an RT-specific hypothesis (11.1%), compared with ST-related hypotheses (77.1%; P < .001); trials were more likely to test an RT-hypothesis if the study PI was a radiation oncologist (20.9% vs 6.0%; P < .001). Among RT trials, most early-phase studies tested novel modalities (eg, stereotactic body radiation therapy, proton therapy), whereas most later-phase studies tested dose and fractionation. RT-focused trials had low rates of federal (10.4%) or industry (2.6%) funding.RT-specific research hypotheses are a minority of phase II-III HNC trials, which mostly focus on incorporating ST in the definitive or recurrent/metastatic setting and have higher rates of industry funding. Radiation oncologist PI leadership and increased nonindustry funding access may ensure that RT-specific hypotheses are incorporated into trial design." @default.
• W3100291706 created "2020-11-23" @default.
• W3100291706 creator A5024024612 @default.
• W3100291706 creator A5024038350 @default.
• W3100291706 creator A5044221282 @default.
• W3100291706 creator A5055709149 @default.
• W3100291706 creator A5067347913 @default.
• W3100291706 creator A5073653003 @default.
• W3100291706 creator A5077566206 @default.
• W3100291706 date "2021-05-01" @default.
• W3100291706 modified "2023-10-17" @default.
• W3100291706 title "Head and Neck Cancer Clinical Research on ClinicalTrials.gov: An Opportunity for Radiation Oncologists" @default.
• W3100291706 cites W2034646939 @default.
• W3100291706 cites W2089257078 @default.
• W3100291706 cites W2168488550 @default.
• W3100291706 cites W2298732689 @default.
• W3100291706 cites W2310008233 @default.
• W3100291706 cites W2803441819 @default.
• W3100291706 cites W2941651034 @default.
• W3100291706 doi "https://doi.org/10.1016/j.adro.2020.10.021" @default.
• W3100291706 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7966829" @default.
• W3100291706 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33748541" @default.
• W3100291706 hasPublicationYear "2021" @default.
• W3100291706 type Work @default.
• W3100291706 sameAs 3100291706 @default.
• W3100291706 citedByCount "2" @default.
• W3100291706 countsByYear W31002917062021 @default.
• W3100291706 countsByYear W31002917062023 @default.
• W3100291706 crossrefType "journal-article" @default.
• W3100291706 hasAuthorship W3100291706A5024024612 @default.
• W3100291706 hasAuthorship W3100291706A5024038350 @default.
• W3100291706 hasAuthorship W3100291706A5044221282 @default.
• W3100291706 hasAuthorship W3100291706A5055709149 @default.
• W3100291706 hasAuthorship W3100291706A5067347913 @default.
• W3100291706 hasAuthorship W3100291706A5073653003 @default.
• W3100291706 hasAuthorship W3100291706A5077566206 @default.
• W3100291706 hasBestOaLocation W31002917061 @default.
• W3100291706 hasConcept C126322002 @default.
• W3100291706 hasConcept C143998085 @default.
• W3100291706 hasConcept C168563851 @default.
• W3100291706 hasConcept C2776530083 @default.
• W3100291706 hasConcept C509974204 @default.
• W3100291706 hasConcept C535046627 @default.
• W3100291706 hasConcept C71924100 @default.
• W3100291706 hasConceptScore W3100291706C126322002 @default.
• W3100291706 hasConceptScore W3100291706C143998085 @default.
• W3100291706 hasConceptScore W3100291706C168563851 @default.
• W3100291706 hasConceptScore W3100291706C2776530083 @default.
• W3100291706 hasConceptScore W3100291706C509974204 @default.
• W3100291706 hasConceptScore W3100291706C535046627 @default.
• W3100291706 hasConceptScore W3100291706C71924100 @default.
• W3100291706 hasFunder F4320307776 @default.
• W3100291706 hasIssue "3" @default.
• W3100291706 hasLocation W31002917061 @default.
• W3100291706 hasLocation W31002917062 @default.
• W3100291706 hasLocation W31002917063 @default.
• W3100291706 hasLocation W31002917064 @default.
• W3100291706 hasOpenAccess W3100291706 @default.
• W3100291706 hasPrimaryLocation W31002917061 @default.
• W3100291706 hasRelatedWork W1993267564 @default.
• W3100291706 hasRelatedWork W2081233187 @default.
• W3100291706 hasRelatedWork W2086793060 @default.
• W3100291706 hasRelatedWork W2110125130 @default.
• W3100291706 hasRelatedWork W2384708512 @default.
• W3100291706 hasRelatedWork W2403481407 @default.
• W3100291706 hasRelatedWork W2434030757 @default.
• W3100291706 hasRelatedWork W2553255798 @default.
• W3100291706 hasRelatedWork W2975801025 @default.
• W3100291706 hasRelatedWork W2989564830 @default.
• W3100291706 hasVolume "6" @default.
• W3100291706 isParatext "false" @default.
• W3100291706 isRetracted "false" @default.
• W3100291706 magId "3100291706" @default.
• W3100291706 workType "article" @default.